UCSF Helen Diller Family Comprehensive Cancer Center | Strategic Alliance Partners

May 25, 2021

Julie Ann Sosa, MD, MA, FACS, FSSO, discusses risk factors for thyroid cancer.

May 10, 2021

Nina Shah, MD, discusses the newfound role of BCMA-directed CAR T-cell therapies in multiple myeloma, how the field may select between ide-cel and cilta-cel if the latter is approved, and novel cellular therapies in clinical development.

April 28, 2021

Nina Shah, MD, discusses the efficacy and safety data observed with ciltacabtagene autoleucel in relapsed/refractory multiple myeloma.

April 23, 2021

Nina Shah, MD, discusses potential future directions with CAR T-cell therapy in multiple myeloma.

April 21, 2021

Nina Shah, MD, discusses the clinical significance of idecabtagene vicleucel for the treatment of patients with multiple myeloma.

April 07, 2021

Nina Shah, MD, discusses the management of CAR T-cell therapy–related toxicities in multiple myeloma.